HOME >> BIOLOGY >> NEWS
William C. Aird, MD, receives Established Investigator Award from American Heart Association

BOSTON William C. Aird, MD, Associate Director of the Vascular Biology Research Center at Beth Israel Deaconess Medical Center (BIDMC), has been named the recipient of a 2005 Established Investigator Award from the National Research Committee of the American Heart Association (AHA).

One of only 25 scientists to receive the AHA's prestigious award, which consists of a five-year $500,000 grant, Aird specializes in investigating endothelial cell heterogeneity, widely believed to play a critical role in both homeostasis and vascular disease states. Aird's laboratory will use the award in their continued investigations of the mechanisms that underlie differential gene expression within the endothelium and to gain a better understanding of how the endothelial cells lining the body's blood vessels are differentially regulated in space and time.

"Bill Aird's work has greatly advanced our thinking about the critical role of the endothelium to health and disease states," notes Jeffrey S. Flier, MD, BIDMC's Chief Academic Officer. "This well-deserved honor from the AHA further serves to demonstrate the fundamental importance of this area of research within the field of medicine."

A graduate of The University of Western Ontario Medical School, Aird completed residencies at St. Michael's Hospital and Toronto General Hospital, teaching hospitals of the University of Toronto. Before joining BIDMC in 1996, he held both clinical and research fellowships in medicine at Brigham and Women's Hospital, and was a postdoctoral fellow in the Department of Biology at the Massachusetts Institute of Technology. He is an Associate Professor of Medicine at Harvard Medical School.

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a res
'"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
10-Feb-2005


Page: 1 2

Related biology news :

1. SNMTS provides $50,000 in 2007 Paul Cole, Mickey Williams Minority Student Technologist Scholarships
2. Williams College biologist explores photosynthetic apparatus
3. Beyond nature vs. nurture: Williams syndrome across cultures
4. APS research awards go to undergrads at Colorado State, Michigan State, Oberlin, Williams
5. Lawrence Platt, MD, receives the 2006 AIUM William J. Fry Memorial Lecture award
6. NSF awards support for DNA analysis instrumentation lab at Williams College
7. Society of Nuclear Medicine to offer $10,000 William L. Ashburn, M.D., Pilot Research Grant for 2006
8. William C. Rose Award lecture will focus on cytochrome P450
9. Carnegie Mellons Peter Adams receives EPA research grant
10. Philadelphia ecologist receives top Mongolia honor
11. VIB scientist receives major research grant

Post Your Comments:
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... DUBLIN , May 20, 2015 Research ... announced the addition of the "2015 Global ... to their offering. The primary goal ... of flow cytometry instruments and reagents. Key information ... drive the selection of flow cytometers, predominantly used ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
Cached News: